[Topics for clinical research.]

Abstract

Results from phase 3 study of a new drug along with effects of longer duration of a currently used drug for osteoporosis were presented. While there were several papers concerning odanacatib, the clinical development of this drug was announced to be terminated just before the meeting. In addition, low treatment rate for patients with osteoporosis because of fear for rare adverse events was emphasized to be a crisis in the treatment of osteoporosis. Finally, a new treatment for hypophosphatemic diseases was introduced. There are many clinically important topics in this meeting.